Kishor Bhatia
Förmögenhet: - $ per 2026-08-31
Förmögenhet: - $ per 2026-08-31
Kishor G.
Bhatia currently works at Lantern Pharma, Inc., as Chief Scientific Officer from 2019.
Dr. Bhatia also formerly worked at National Cancer Institute, as Director-AIDS Malignancy Program from 2007 to 2016 and Georgetown University, as Research Assistant Professor from 1985 to 1989.
Dr. Bhatia received his doctorate degree from the University of Mumbai and undergraduate degree from the University of Pune.
| Företag | Datum | Antal aktier | Värdering | Värderingsdatum |
|---|---|---|---|---|
LANTERN PHARMA, INC. -.--% | 2026-04-17 | 0 ( -.--% ) | - $ | 2026-08-31 |
| Företag | Position | Start |
|---|---|---|
| LANTERN PHARMA INC. | Teknisk/Vetenskaplig/F&U Direktör | 2019-12-01 |
| Företag | Position | Slut |
|---|---|---|
National Cancer Institute
National Cancer Institute Investment Trusts/Mutual FundsMiscellaneous Conducts research projects & awards grants for cancer research | Företagsledare/Principal | 2016-07-01 |
Georgetown University
Georgetown University Other Consumer ServicesConsumer Services Functions as a College/University | Företagsledare/Principal | 1989-01-01 |
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Första gradens relationer
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
| Privata företag | 5 |
|---|---|
University of Mumbai
University of Mumbai Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Georgetown University
Georgetown University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
National Cancer Institute
National Cancer Institute Investment Trusts/Mutual FundsMiscellaneous Conducts research projects & awards grants for cancer research | Miscellaneous |
University of Pune
University of Pune Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Lantern Pharma, Inc.
Lantern Pharma, Inc. Pharmaceuticals: MajorHealth Technology Develops cancer drug from advanced genomics and artificial intelligence | Health Technology |
Välj din utgåva
All finansiell information anpassad till den nationella nivån